Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 192 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HR+ HER2- Breast Cancer Clear all
Completed No phase listed Observational Results available

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

NCT04602117
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985, Vic-trastuzumab Duocarmazine, Metastatic Cancer, Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic, HER2 Low Breast Cancer, GastroEsophageal Cancer, Gastroesophageal Adenocarcinoma, Endometrium Tumor, Ovarian Cancer, Ovarian Carcinoma, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2 Low HR Positive, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Bladder Cancer
Interventions
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Irvine, California • Los Angeles, California • Newport Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

NCT04791384
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Elacestrant
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Aurora, Colorado • Miami Beach, Florida • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

NCT03822468
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Anastrozole, Letrozole, Goserelin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 3 Interventional

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886
View directory record Official record
Conditions
Breast Cancer
Interventions
Gedatolisib, Palbociclib, Fulvestrant, Alpelisib
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
71
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 1 Interventional

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

NCT05996107
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Postoperative Radiation Therapy
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Ann Arbor, Michigan • Wyoming, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 4 Interventional

Roll-over Study to Allow Continued Access to Ribociclib

NCT05161195
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
16
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

NCT07512063
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients

NCT07760714
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn Phase 4 Interventional

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

NCT03988114
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
70
States / cities
Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational Results available

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

NCT06086340
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib, Aromatase Inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 1 Interventional

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

NCT07383506
View directory record Official record
Conditions
PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer
Interventions
CGT6297
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

NCT01528345
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dovitinib, Fulvestrant, Dovitinib Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

NCT04448886
View directory record Official record
Conditions
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab Govitecan
Drug
Lead sponsor
Ana C Garrido-Castro, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 3 Interventional

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

NCT04906395
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Greenbrae, California • Parker, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

NCT05153135
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ribociclib, Palbociclib, Abemaciclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
4,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

VS-6766+Abema+Fulv in Met HR+/HER- BC

NCT05608252
View directory record Official record
Conditions
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
VS-6766, Abemaciclib, Fulvestrant
Drug
Lead sponsor
Adrienne G. Waks
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

NCT02154776
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
LEE011, Buparlisib, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Lafayette, Indiana • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521
View directory record Official record
Conditions
PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
Zovegalisib, Capivasertib, Fulvestrant
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
52
States / cities
Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

NCT04481113
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
Interventions
Abemaciclib, Niraparib Tosylate Monohydrate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

NCT04923542
View directory record Official record
Conditions
Brain Metastases, HR+ Metastatic Breast Cancer
Interventions
Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 17, 2026, 4:09 AM EDT